Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen-receptor-positive Breast Cancer|HER2/Neu-Negative Breast Cancer|Advanced Breast Cancerv|Metastatic Breast Cancer
Interventions: DRUG: elacestrant, palbociclib, abemaciclib, ribociclib
Sponsor: Northwestern University
Collaborators: National Cancer Institute (NCI)